Mild cognitive disorder

1. Metformin + GLP-1 receptor agonists lower the risk of mild cognitive disorder in humans (HR 0.79, 95% CI 0.66-0.95).

   Humanstype 2 diabetes, versus metformin only

   Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

   PloS one·24 Aug 2026

More on Metformin + GLP-1 receptor agonists